Tools4Patient Announces Name Change to Cognivia
Cognivia announced a new name for the company formerly known as Tools4Patient. The transition to Cognivia more closely reflects the company's mission to “quantify the power of the mind” and integrate this information into data analyses to optimize and accelerate drug development.
This name change expresses the evolution of the company since it was founded eight years ago. As part of this maturation, Cognivia has built the evidence basis for its technologies through multiple clinical trials and has become a partner of pharma companies, biotechs, and CROs. Cognivia’s solutions are focused in areas that have posed significant challenges to drug development, including the placebo response and medication adherence in clinical trials.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
